S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
NASDAQ:INGN

Inogen (INGN) Stock Forecast, Price & News

$5.27
-0.09 (-1.68%)
(As of 12:39 PM ET)
Compare
Today's Range
$5.19
$5.43
50-Day Range
$5.14
$8.58
52-Week Range
$5.05
$26.11
Volume
64,556 shs
Average Volume
313,691 shs
Market Capitalization
$122.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Inogen MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
168.2% Upside
$14.00 Price Target
Short Interest
Healthy
2.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
-0.03mentions of Inogen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.35) to ($2.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

436th out of 970 stocks

Surgical Appliances & Supplies Industry

10th out of 20 stocks


INGN stock logo

About Inogen (NASDAQ:INGN) Stock

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; and related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

INGN Price History

INGN Stock News Headlines

Inogen, Inc. (NASDAQ:INGN) Sees Significant Growth in Short Interest
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Inogen Closes Acquisition Of Physio-Assist SAS
Inogen Completes Acquisition of Physio-Assist
JP Morgan Downgrades Inogen (INGN)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Inogen: Q2 Earnings Snapshot
Earnings Preview For Inogen
Inogen (NASDAQ: INGN)
Will the Current Downturn Affect Inogen (INGN)?
See More Headlines
Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Company Calendar

Last Earnings
8/07/2023
Today
9/29/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INGN
Fax
N/A
Employees
1,026
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+161.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-83,770,000.00
Pretax Margin
-27.44%

Debt

Sales & Book Value

Annual Sales
$377.24 million
Book Value
$12.98 per share

Miscellaneous

Free Float
23,046,000
Market Cap
$124.30 million
Optionable
Optionable
Beta
0.98

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Nabil Shabshab (Age 58)
    CEO, Pres & Director
    Comp: $943k
  • Mr. Michael K. Sergesketter (Age 63)
    Interim Exec. VP, Chief Financial Officer & Treasurer
    Comp: $227.53k
  • Dr. Stanislav Glezer M.D. (Age 50)
    MBA, Exec. VP & CTO
    Comp: $575.8k
  • Mr. Jason Somer (Age 55)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $409.92k
  • Ms. Jennifer Yi Boyer
    Exec. VP & Chief HR Officer
  • Mr. Vijay Paliwal
    Sr. VP of Enterprise Enablement
  • Mr. Matthew Pigeon
    Investor Relations Officer













INGN Stock - Frequently Asked Questions

Should I buy or sell Inogen stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings
or view top-rated stocks.

What is Inogen's stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price objectives for Inogen's shares. Their INGN share price forecasts range from $8.00 to $26.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for INGN
or view top-rated stocks among Wall Street analysts.

How have INGN shares performed in 2023?

Inogen's stock was trading at $19.71 at the beginning of the year. Since then, INGN stock has decreased by 72.8% and is now trading at $5.36.
View the best growth stocks for 2023 here
.

Are investors shorting Inogen?

Inogen saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 639,200 shares, an increase of 29.7% from the August 31st total of 492,900 shares. Based on an average trading volume of 277,300 shares, the short-interest ratio is currently 2.3 days.
View Inogen's Short Interest
.

When is Inogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our INGN earnings forecast
.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) issued its earnings results on Monday, August, 7th. The medical technology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.22. The medical technology company earned $83.64 million during the quarter, compared to the consensus estimate of $92.20 million. Inogen had a negative trailing twelve-month return on equity of 14.95% and a negative net margin of 27.57%. The business's quarterly revenue was down 19.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) earnings per share.

What guidance has Inogen issued on next quarter's earnings?

Inogen updated its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $315.00 million-$320.00 million, compared to the consensus revenue estimate of $316.73 million.

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $5.36.

How much money does Inogen make?

Inogen (NASDAQ:INGN) has a market capitalization of $124.30 million and generates $377.24 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis.

How many employees does Inogen have?

The company employs 1,026 workers across the globe.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.

This page (NASDAQ:INGN) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -